Is the Supreme Court’s Review of Amarin v. Hikma Only an Issue for the Pharma Industry?

The decision by the Supreme Court of the United States to review Amarin v. Hikma places renewed focus on a recurring challenge in patent law: how to balance the economies of generic competition with the need for meaningful incentives for innovation. While the case comes out of the pharmaceutical industry, its implications could also directly extend into the agrichemical industry and may also extend into other regulated technology sectors where method-based patents and government-regulated uses play a central role.

For innovators building IP portfolios around pharmaceuticals, biologics, agricultural inputs, or functional food technologies, the Court’s eventual ruling could influence patent drafting strategies, product labelling and marketing, and investment decisions around clinical trials and regulatory approvals.

Skinny labels, induced infringement, and method-of-use patents

At the center of the dispute is the concept of a “skinny label.” Under the Hatch-Waxman Act, a generic manufacturer may seek FDA approval while carving out patented indications from its label, allowing the product to enter the market for non-patented uses. In theory, this approach preserves competition while respecting valid patent rights.

The branded product at issue in Amarin v. Hikma, Vascepa^®, first received approval for reduction of blood triglyceride levels. After later successful clinical trials, Amarin sought and received approval for a cardiovascular (CV) indication protected by method-of-use patents. Hikma launched a generic version with a skinny label that carved out the protected CV indication, but Amarin alleged that Hikma’s broader marketing and public communications still encouraged physicians to prescribe the product for the patented CV use.

The Federal Circuit concluded that Amarin’s allegations were sufficient to proceed with a case of induced infringement, emphasizing that inducement should be assessed based on the totality of conduct—not labeling alone. Hikma has now asked the Supreme Court to decide where that boundary should be drawn, and the current administration, through U.S. Solicitor General D. John Sauer, is lending its support to Hikma, citing concerns about a chilling effect on the availability of lower-cost generics.

A likely ruling—and why it matters for other areas of innovation

We expect the Supreme Court to side with Hikma and the government, reinforcing the purposes underlying skinny labels and limiting the scope of future induced infringement cases. However, from an IP strategy perspective, any clarity arising from the Supreme Court ruling may come with trade-offs by allowing generics to rely on form-over-substance arguments to escape infringement claims.

The current regulatory and patent systems already tend to favor new molecular entities over new uses of known compounds. New molecules benefit from longer exclusivity periods, stronger patent positioning, and more predictable returns on investment. Developing secondary or alternative indications for existing drugs often requires extensive and expensive clinical trials with more limited potential for patent protection and investment recovery. And allowing generics to skirt inducement of additional protected indications simply by carving them out on a skinny label, no matter how strongly they promote off-label uses, will make investment in those follow-on clinical trials even less attractive.

This concern is not limited to pharmaceuticals. Similar dynamics exist in agricultural chemistry, where a generic agrichemical label must be consistent with, but not necessarily identical to, the reference product’s label. Oftentimes, patent infringement and validity issues that first arise in the context of pharmaceutical litigation later surface in patent disputes in other technology areas as well. Persons in any technology area where known compounds or organisms are repurposed for new functional or therapeutic uses should pay attention to how the Supreme Court addresses the issues before it in Amarin.

Implications for IP portfolio development and regulatory strategy

For companies working with Baldwin IP on patent prosecution, portfolio management, and IP counseling, this case highlights the importance of aligning patent strategy with regulatory realities. Method-of-use patents remain valuable, but their enforcement increasingly depends on how products are described, marketed, and positioned in the marketplace.

The Amarin case also underscores the need for careful coordination between patent drafting, regulatory strategy, and commercialization planning. Marketing language, investor communications, and public disclosures may all become relevant evidence in inducement disputes, particularly where products are capable of both patented and non-patented uses.

Looking ahead

Regardless of how the Supreme Court rules, Amarin v. Hikma is a reminder that patent law does not operate in isolation. For innovators in pharmaceuticals, biotechnology, agribusiness, and food science, success increasingly depends on an integrated IP strategy—one that accounts for patent enforcement, regulatory compliance, and real-world market behavior.

As the Court weighs these issues, companies would be well served to reassess how their IP portfolios protect not only new inventions, but also the evolving uses that give those technologies long-term value.